REDCap, the research data management tool created and powered by Vanderbilt University Medical Center, is serving extra duty as research teams and public health authorities around the world grapple with the COVID-19 pandemic.

After evaluating the ability of more than 1,500 monoclonal antibodies to bind and neutralize the COVID-19 virus, SARS-CoV-2, in the laboratory, AstraZeneca signed an exclusive license to six candidate antibodies in Vanderbilt’s portfolio.

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

As of early May, an average of 8,000 VUMC employees were working remotely each day, equaling more than 25% of VUMC’s total workforce.

There has been nothing normal about the COVID-19 pandemic, and grieving the loss of a life at a time when families have been unable to gather beside a bedside to say goodbye, or to even hold a traditional funeral, has been one of the worst consequences of this health crisis’s uncharted territory.

Pediatricians at Monroe Carell Jr. Children’s Hospital at Vanderbilt are stressing the continued importance of well-child visit for infants, children and adolescents, particularly during the COVID-19 pandemic.

People with cancer sickened by COVID-19 have a crude death rate of 13%, according to the largest series of data released thus far from a multinational perspective. The data on more than 900 patients, published May 28 in The Lancet and simultaneously presented at ASCO20 Virtual, also revealed cancer-specific factors associated with increased mortality.